You are here: Home / Studies / Population based surveillance for colonization or infection with carbapenamse producing Enterobacterales (CPE)

Population based surveillance for colonization or infection with carbapenamse producing Enterobacterales (CPE)

Status:  Currently Recruiting

Why are we doing this?

CPE are a type of antimicrobial resistance rated as one of the highest antimicrobial resistant threats by both the World Health Organization and the United States CDC.

Our goal is to continue to provide clinicians in south-central Ontario with information about how this new form of antimicrobial is evolving, and how it is best prevented and managed.


  • To describe the incidence, clinical features and outcomes of colonization/infection with CPE
  • To assess the risk of infection in persons identified as colonized with CPE
  • To determine the rate of transmission of CPE within households
  • To assess the duration of colonization with CPE, and factors associated with persistent colonization.

Who is being asked to participate?

  • Anyone who is a resident of Toronto and Peel Region and who is identified as colonized or infected with CPE

If I agree to participate, what will I need to do?

If you agree to participate you will be consenting to:

  • being interviewed for approximately 10-15 minutes risk factors for exposure to CPE
  • the release of information about you medical history from the hospital
  • the release of information about previous vaccinations and antibiotics from your family doctor
  • having any left-over specimens that tested positive for CPE sent to the study laboratory for storage and possible future testing.
  • Considering participating in studies of how long CPE colonization persists and whether it can be passed on to close household contacts.

How long will the study last?

This study has been running since 2015 at all TIBDN hospitals.

Are there any risks to participating in this study?

There are no physical risks for you in taking part in this study. You are not being given any medication and no change in your treatment will result from your participation. You may find the interviews or questions upsetting or distressing or you may not like all of the questions that you are asked. You may refuse to answer questions or stop interviews at any time if you are uncomfortable. We take every precaution to protect your personal information. Any information and left-over test sample you provide to the study is confidential and is identified only by a study code number. No one will be able to identify the study information or sample as belonging to you.

Who can I contact if I am interested in the study? 

Call the study office at Mount Sinai Hospital, 416-586-4800, ext. 2761 or 1-800-668-6292.

You will be directed to the TIBDN research personnel assigned to the hospital where you were admitted.


Dr. Allison McGeer, Principal Investigator